X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (106) 106
humans (101) 101
commonly deleted region (93) 93
oncology (56) 56
myelodysplastic syndromes - genetics (50) 50
chromosome deletion (46) 46
hematology (45) 45
myelodysplastic syndromes (41) 41
male (38) 38
female (37) 37
acute myeloid-leukemia (26) 26
animals (26) 26
chromosomes, human, pair 5 - genetics (26) 26
genetics & heredity (26) 26
aged (25) 25
leukemia (23) 23
middle aged (23) 23
molecular delineation (23) 23
commonly deleted segment (22) 22
prognosis (22) 22
in situ hybridization, fluorescence (21) 21
adult (20) 20
chromosome aberrations (17) 17
lenalidomide (17) 17
myelodysplastic syndrome (17) 17
identification (16) 16
loss of heterozygosity (16) 16
mice (16) 16
mutation (16) 16
thalidomide - analogs & derivatives (16) 16
thalidomide - therapeutic use (16) 16
chromosome mapping (15) 15
leukemia, myeloid, acute - genetics (15) 15
malignant myeloid diseases (15) 15
5q-syndrome (14) 14
aged, 80 and over (14) 14
genes, tumor suppressor (14) 14
genetic aspects (14) 14
long arm (14) 14
myelodysplastic syndromes - pathology (14) 14
tumor-suppressor gene (14) 14
biochemistry & molecular biology (13) 13
cancer (13) 13
cell biology (13) 13
chromosomes, human, pair 5 (13) 13
cytogenetics (13) 13
karyotyping (13) 13
myelodysplastic syndromes - drug therapy (13) 13
research (13) 13
acute lymphoblastic-leukemia (12) 12
analysis (12) 12
article (12) 12
cytogenetic analysis (12) 12
del (12) 12
expression (12) 12
hematology, oncology and palliative medicine (12) 12
leukemia, myeloid - genetics (12) 12
haploinsufficiency (11) 11
in-situ hybridization (11) 11
myeloproliferative disorders (11) 11
prognostic-significance (11) 11
acute myelogenous leukemia (10) 10
child (10) 10
chromosome 5q deletion (10) 10
chromosomes, human, pair 7 - genetics (10) 10
diamond-blackfan anemia (10) 10
gene deletion (10) 10
heterozygosity (10) 10
risk factors (10) 10
antineoplastic agents - therapeutic use (9) 9
care and treatment (9) 9
chromosomes, human, pair 7 (9) 9
gene (9) 9
mds (9) 9
molecular sequence data (9) 9
acute disease (8) 8
adolescent (8) 8
anemia, macrocytic - genetics (8) 8
chronic myelomonocytic leukemia (8) 8
deletions (8) 8
delineation (8) 8
frequent loss (8) 8
gene expression profiling (8) 8
microsatellite repeats (8) 8
myelodysplastic syndromes - diagnosis (8) 8
polymorphism, single nucleotide (8) 8
translocation, genetic (8) 8
abnormalities (7) 7
amino acid sequence (7) 7
comparative genomic hybridization (7) 7
genes (7) 7
genetic research (7) 7
hematologic neoplasms - genetics (7) 7
myeloid malignancies (7) 7
myeloproliferative disorders - genetics (7) 7
rna (7) 7
therapy-related myelodysplasia (7) 7
tumor suppressor genes (7) 7
tumors (7) 7
abridged index medicus (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


NATURE, ISSN 0028-0836, 07/2015, Volume 523, Issue 7559, pp. 183 - U102
Lenalidomide is a highly effective treatment for myelodysplastic syndrome (MDS) with deletion of chromosome 5q (del(5q)). Here, we demonstrate that... 
MULTIPLE-MYELOMA | CELLS | COMPLEX | COMMONLY DELETED REGION | GENE | MULTIDISCIPLINARY SCIENCES | 5Q-SYNDROME | THALIDOMIDE | CASEIN KINASE | IDENTIFICATION | MYELODYSPLASTIC SYNDROMES
Journal Article
BLOOD, ISSN 0006-4971, 01/2012, Volume 119, Issue 1, pp. 206 - 216
Deletions of chromosome 5q are associated with poor outcomes in acute myeloid leukemia (AML) suggesting the presence of tumor suppressor(s) at the locus.... 
CELLS | COMMONLY DELETED REGION | DNA METHYLATION | RNA | PKR | TUMOR-SUPPRESSOR GENE | MELTING ANALYSIS | ACUTE MYELOID-LEUKEMIA | IDENTIFICATION | HEMATOLOGY | MYELODYSPLASTIC SYNDROME
Journal Article
PLOS ONE, ISSN 1932-6203, 02/2017, Volume 12, Issue 2
Myelodysplastic syndromes (MDS) are the most common adult myeloid blood cancers in the US. Patients have increased apoptosis in their bone marrow cells leading... 
HUMAN 5Q-SYNDROME | COMMONLY DELETED REGION | DEL(5Q) MDS | HSP70 | GENE | MULTIDISCIPLINARY SCIENCES | P53 FUNCTION | MUTATIONS | MYELODYSPLASTIC SYNDROMES | INEFFECTIVE HEMATOPOIESIS | HAPLOINSUFFICIENCY
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2012, Volume 30, Issue 12, pp. 1343 - 1349
Journal Article
PLoS Medicine, ISSN 1549-1277, 02/2008, Volume 5, Issue 2, pp. 0312 - 0322
Background Lenalidomide is an effective new agent for the treatment of patients with myelodysplastic syndrome (MDS), an acquired hematopoietic disorder... 
APOPTOSIS | MEDICINE, GENERAL & INTERNAL | COMMONLY DELETED REGION | DISEASES | SET ENRICHMENT ANALYSIS | CLASSIFICATION | PROLIFERATION | THALIDOMIDE | CHROMOSOME-5 | TISSUES | DISCOVERY | Predictive Value of Tests | Erythroid Precursor Cells - drug effects | Humans | Middle Aged | Erythropoiesis - drug effects | Male | Myelodysplastic Syndromes - blood | Thalidomide - pharmacology | Erythroid Precursor Cells - physiology | Cell Differentiation - genetics | Thalidomide - analogs & derivatives | Aged, 80 and over | Hematopoietic Stem Cells - physiology | Adult | Chromosomes, Human, Pair 5 - drug effects | Myelodysplastic Syndromes - drug therapy | Chromosomes, Human, Pair 5 - genetics | Erythropoiesis - genetics | Chromosome Deletion | Hematopoietic Stem Cells - drug effects | Cells, Cultured | Gene Expression Profiling - methods | Genetic Markers - drug effects | Cell Differentiation - drug effects | Genetic Markers - genetics | Aged | Myelodysplastic Syndromes - genetics | Clinical Trials, Phase II as Topic - methods | Thalidomide - therapeutic use | Index Medicus | Genetics and Genomics | Oncology | Chemotherapy | Hematology (including Blood Transfusion) | Hematology | Medical research | Transplants & implants | Cytokines | Leukemia | Colonies & territories | Gene expression | Experiments | Cancer therapies | Blood clots | Defects | Studies | Confidence intervals | Bone marrow | Chromosomes | Drug dosages | Cancer
Journal Article
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 4, pp. 6483 - 6495
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2017, Volume 12, Issue 1, pp. e0169767 - e0169767
An understanding of how each individual 5q chromosome critical deleted region (CDR) gene contributes to malignant transformation would foster the development... 
CANCER-CELLS | TRANSFORMATION | IN-VITRO | COMMONLY DELETED REGION | GENE | MULTIDISCIPLINARY SCIENCES | TRANSCRIPTION FACTOR EGR-1 | MALIGNANT MYELOID DISEASES | MYELODYSPLASTIC SYNDROME | EXPRESSION | MOLECULAR DELINEATION | Whole-Body Irradiation | Apoptosis - radiation effects | Bone Marrow Cells - cytology | Up-Regulation - radiation effects | Cells, Cultured | Tumor Suppressor Protein p53 - metabolism | Bone Marrow Cells - radiation effects | RNA, Messenger - metabolism | Tumor Suppressor Protein p53 - genetics | DNA Breaks, Double-Stranded - radiation effects | Tibia - cytology | Animals | Histones - genetics | Early Growth Response Protein 1 - genetics | Mice | Histones - metabolism | Real-Time Polymerase Chain Reaction | Bone Marrow Cells - metabolism | Early Growth Response Protein 1 - metabolism | Microscopy, Fluorescence | Radiation, Ionizing | Ionizing radiation | Growth | Causes of | Physiological aspects | Research | Tumor proteins | Hematopoietic stem cells | Apoptosis | Transformation | Transcription | p53 Protein | Leukemia | Lung cancer | DNA damage | Radiation | Cancer therapies | Neoplasms | Proteins | Toxicology | Immunology | Bone marrow | Genetics | Chromosomes | Deoxyribonucleic acid--DNA | Radiation effects | Medical research | Hematology | EGR-1 protein | Gene expression | Ribonucleic acid--RNA | Hemopoiesis | Signaling | Medical prognosis | Stem cells | Lymphomas | Transformations | Mutation | Bone | Aberration | Prostate | Tumors | Index Medicus | RNA | Deoxyribonucleic acid | Ribonucleic acid | DNA
Journal Article